Impact of the composition of gastric reflux bile acids on Barrett's oesophagus

Digestive and Liver Disease

Volumn 43, Issue 9, 2011, Pages 692-697

  Takahashi, Yoshiko ^a   Amano, Yuji ^b   Yuki, Takafumi ^b   Mishima, Yuko ^a   Tamagawa, Yuji ^a   Uno, Goichi ^b   Ishimura, Norihisa ^a   Sato, Shuichi ^a   Ishihara, Shunji ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Barrett's oesophagus; COX 2; Erosive oesophagitis; Reflux bile acids

Indexed keywords

BILE ACID; CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; BILE HYDROPHOBICITY RATIO; CELL PROLIFERATION; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN TISSUE; HYDROPHILICITY; HYDROPHOBICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; STOMACH JUICE;

AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BILE REFLUX; BONE MORPHOGENETIC PROTEIN 4; CHOLIC ACIDS; CYCLOOXYGENASE 2; FEMALE; GASTRIC JUICE; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 79961127884     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.02.021     Document Type: Article

References (58)

1. Kauer W.K., Peters J.H., DeMeester T.R., et al. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 1995, 222:525-533.
2. Vaezi M.F., Richter J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996, 111:1192-1199.
3. Fein M., Maroske J., Fuchs K.H. Importance of duodenogastric reflux in gastro-oesophageal reflux disease. Br J Surg 2006, 93:1475-1482.
4. Attwood S.E., Ball C.S., Barlow A.P., et al. Role of intragastric and intraoesophageal alkalinisation in the genesis of complications in Barrett's columnar lined lower oesophagus. Gut 1993, 34:11-15.
5. Zaninotto G., Portale G., Parenti A., et al. Role of acid and bile reflux in development of specialised intestinal metaplasia in distal oesophagus. Dig Liver Dis 2002, 34:251-257.
6. Wolfgarten E., Pütz B., Hölscher A.H., et al. Duodeno-gastric-esophageal reflux-what is pathologic? Comparison of patients with Barrett's esophagus and age-matched volunteers. J Gastrointest Surg 2007, 11:479-486.
7. Champion G., Richter J.E., Vaezi M.F., et al. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994, 107:747-754.
8. Kauer W.K., Peters J.H., DeMeester T.R., et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 1997, 122:874-881.
9. Sarela A.I., Hick D.G., Verbeke C.S., et al. Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. Arch Surg 2004, 139:547-551.
10. Kazumori H., Ishihara S., Rumi M.A.K., et al. Bile acid directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 2005, 55:16-25.
11. Jaiswal K., Lopez-Guzman C., Souza R.F., et al. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol 2006, 290:G335-G342.
12. Miwa K., Sahara H., Hattori T., et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer 1995, 67:269-274.
13. Kaur B.S., Triadafilopoulos G. Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's esophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002, 283:G327-G334.
14. Chen K.H., Mukaisho K., Sugihara H., et al. High animal fat intake changes the bile acid composition of bile juice and enhances the development of Barrett's esophagus and esophageal adenocarcinoma in a rat duodenal-contents reflux model. Cancer Sci 2007, 98:1683-1688.
15. Amano Y., Ishimura N., Furuta K., et al. Which landmark results in a more consistent diagnosis of Barrett's esophagus, the gastric folds or the palisade vessels?. Gastrointest Endosc 2006, 64:206-211.
16. Sharma P., Dent J., Armstrong D., et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006, 131:1392-1399.
17. Armstrong D. Review article: towards consistency in the endoscopic diagnosis of Barrett's oesophagus and columnar metaplasia. Aliment Pharmacol Ther 2004, 20(Suppl. 5):40-47.
18. Lundell L.R., Dent J., Bennett J.R., et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999, 45:172-180.
19. Amano K., Adachi K., Katsube T., et al. Role of hiatus hearnia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly. J Gastroenterol Hepatol 2001, 16:132-136.
20. Kimura K., Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969, 3:87-97.
21. Amano Y., Kushiyama Y., Ishihara S., et al. Crystal violet chromoendoscopy with mucosal pit pattern diagnosis is useful for surveillance of short segment Barrett's esophagus. Am J Gastroenterol 2005, 100:21-26.
22. Yuki T., Amano Y., Kushiyama Y., et al. Evaluation of modified crystal violet chromoendoscopy procedure using new mucosal pit pattern classification for detection of Barrett's dysplastic lesions. Dig Liv Dis 2006, 238:296-300.
23. Hofmann A.F., Small D.M. Detergent properties of bile salts: correlation with physiological function. Ann Rev Med 1967, 18:333-376.
24. Carey M.C., Small D.M. The characteristics of mixed micellar solutions with particular reference to bile. Am J Med 1970, 49:590-608.
25. Isomaa B. Interactions of surface-active alkyltrimethylammonium salts with the erythrocyte membrane. Biochem Pharmacol 1979, 28:975-980.
26. Sagawa H., Tazuma S., Kajiyama G. Protection against hydrophobic bile salt-induced cell membrane damage by liposomes and hydrophilic bile salts. Am J Physiol 1993, 264:G835-G839.
27. Shekels L.L., Beste J.E., Ho S.B. Tauroursodeoxycholic acid protects in vitro models of human colonic cancer cells from cytotoxic effects of hydrophobic bile acids. J Lab Clin Med 1996, 127:57-66.
28. Heuman D.M. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res 1989, 30:719-730.
29. Güldütuna S., Zimmer G., Imhof M., et al. Molecular aspects of membrane stabilization by ursodeoxycolate. Gastroenterology 1993, 104:736-744.
30. Thao T.D., Ryu H.C., Yoo S.H., et al. Antibacterial and anti-atrophic effects of a highly soluble, acid stable UDCA formula in Helicobacter pylori-induced gastritis. Biochem Pharmacol 2008, 75:2135-2146.
31. Baiocchi L., Tisone G., Russo M.A., et al. TUDCA prevents cholestasis and canalicular damage induced by ischemia-reperfusion injury in the rat, modulating PKCalpha-ezrin pathway. Transpl Int 2008, 21:792-800.
32. Lillemoe K.D., Kidder G.W., Harmon J.W., et al. Tauroursodeoxycholic acid is less damaging than Taurochenodeoxycholic acid to the gastric and esophageal mucosa. Dig Dis Sci 1983, 28:359-364.
33. Goldman A., Condon A., Adler E., et al. Protective effects of glycoursodeoxycholic acid in Barrett's esophagus cells. Dis Esophagus 2009, 23:83-93.
34. Buttar N.S., Wang K.K., Leontovich O., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122:1101-1112.
35. Amano Y., Ishihara S., Kushiyama Y., et al. Barrett's oesophagus with predominant intestinal metaplasia correlates with superficial cyclo-oxygenase-2 expression, increased proliferation and reduced apoptosis: changes that are partially reversed by non-steroidal anti-inflammatory drugs usage. Aliment Pharmacol Ther 2004, 20:793-802.
36. Milano F., van Ball J.W., Buttar N.S., et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 2007, 132:2412-2421.
37. Wang D.H., Clemons N.J., Miyashita T., et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology 2010, 138:1810-1822.
38. Sampliner R.E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus, The Practice Parameter Committee of the American College of Gastroenterology. Am J Gastroenterol 1998, 93:1028-1032.
39. O'Connor C.J., Wallace R.G., Iwamoto K., et al. Bile salt damage of egg phosphatidylcholine liposomes. Biochim Biophys Acta 1985, 817:95-102.
40. Tack J., Koek G., Demedts I., et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both?. Am J Gastroenterol 2004, 99:981-988.
41. Nehra D., Howell P., Williams C.P., et al. Toxic bile acid in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999, 44:598-602.
42. Jenkins G.J., Harries K., Doak S.H., et al. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-κB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 2004, 25:317-323.
43. Zhou G., Sun Y.G., Wang H.B., et al. Acid and bile salt up-regulate BMP4 expression in human esophageal epithelium cells. Scand J Gastroenterol 2009, 44:926-932.
44. Song S., Guha S., Liu K., et al. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signaling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2007, 56:1512-1521.
45. Invernizzi P., Salzman A.L., Szabó C., et al. Ursodeoxycholate inhibits induction of NOS in human intestinal epithelial cells and in vivo. Am J Physiol 1997, 273:G131-G138.
46. Bernardes-Silva C.F., Damião A.O., Sipahi A.M., et al. Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress. Dig Dis Sci 2004, 49:1569-1574.
47. Dvorak K., Payne C.M., Chavarria M., et al. Bile acid in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 2007, 56:763-771.
48. Wali R.K., Stoiber D., Nguyen L., et al. Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development. Cancer Epidemiol Biomarkers Prev 2002, 11:1316-1321.
49. Wali R.K., Khare S., Tretiakova M., et al. Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol Biomarkers Prev 2002, 11:1653-1662.
50. Ikegami T., Matsuzaki Y., Shoda J., et al. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett 1998, 134:129-139.
51. Khare S., Cerda S., Wali R.K., et al. Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res 2003, 63:3517-3523.
52. Earnest D.L., Holubec H., Wali R.K., et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxy cholic acid. Cancer Res 1994, 54:5071-5074.
53. Alberts D.S., Martínez M.E., Hess L.M., et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005, 97:846-853.
54. Stefaniwsky A.B., Tint G.S., Speck J., et al. Ursodeoxycholic acid treatment of bile reflux gastritis. Gastroenterology 1985, 89:1000-1004.
55. Marteau P., Chazouilléres O., Myara A., et al. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990, 12:1206-1208.
56. Rudolph G., Kloeters-Plachky P., Sauer P., et al. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate. Eur J Clin Invest 2002, 32:575-580.
57. Omata M., Yoshida H., Toyota J., et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 2007, 56:747-753.
58. Bozikas A., Marsman W.A., Rosmolen W.D., et al. The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett's esophagus. Dis Esophagus 2008, 21:346-354.